Synthesis and comparison of 99mTc-enrofloxacin and 99mTc-ciprofloxacin.

Re: synthesis and comparison of 99mTc-enrofloxacin and 99mTc-ciprofloxacin. J Nucl Med (2005) 1.43

Can we produce an image of bacteria with radiopharmaceuticals? Eur J Nucl Med Mol Imaging (2008) 1.01

Expanding role of 18F-fluoro-D-deoxyglucose PET and PET/CT in spinal infections. Eur Spine J (2010) 0.98

Radionuclide imaging of spinal infections. Eur J Nucl Med Mol Imaging (2006) 0.96

Nuclear medicine and the failed joint replacement: Past, present, and future. World J Radiol (2014) 0.91

The many roads to infection imaging. Eur J Nucl Med Mol Imaging (2008) 0.88

Antimicrobial peptides as infection imaging agents: better than radiolabeled antibiotics. Int J Pept (2012) 0.83

Radiotracers used for the scintigraphic detection of infection and inflammation. ScientificWorldJournal (2015) 0.80

Multimodality molecular imaging of the lung. J Magn Reson Imaging (2010) 0.79

Scintigraphic visualization of bacterial translocation in experimental strangulated intestinal obstruction. Eur J Nucl Med Mol Imaging (2009) 0.78

Molecular imaging of bacterial infections in vivo: the discrimination of infection from inflammation. Informatics (MDPI) (2014) 0.77

Imaging bacteria with radiolabelled quinolones, cephalosporins and siderophores for imaging infection: a systematic review. Clin Transl Imaging (2016) 0.77

Preclinical studies and prospective clinical applications for bacteria-targeted imaging: the future is bright. Clin Transl Imaging (2016) 0.75

A Novel Method for the Synthesis of (99m)Tc-Ofloxacin Kits Using D-Penicillamine as Coligand and Their Application as Infection Imaging Agent. Biomed Res Int (2015) 0.75

Bacterial infection imaging with [(18)F]fluoropropyl-trimethoprim. Proc Natl Acad Sci U S A (2017) 0.75

Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80

Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg (2006) 2.62

Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res (2002) 2.38

A novel method of 18F radiolabeling for PET. J Nucl Med (2009) 2.35

Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 2.32

Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging (2004) 2.21

Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol (2013) 2.04

Changes in cerebellar blood flow after manipulation of the cervical spine using Technetium 99m-ethyl cysteinate dimer. J Manipulative Physiol Ther (2005) 2.03

Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹In-labelled exendin. Diabetologia (2014) 2.00

Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol (2010) 1.86

Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J Nucl Med (2009) 1.80

Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med (2010) 1.71

Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos (2006) 1.71

Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging (2006) 1.66

Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis. J Nucl Med (2006) 1.61

99mTc-labeled interleukin 8 for the scintigraphic detection of infection and inflammation: first clinical evaluation. J Nucl Med (2007) 1.61

Patients' and personnel's perceptions of service quality and patient satisfaction in nuclear medicine. Eur J Nucl Med Mol Imaging (2002) 1.58

Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models. J Nucl Med (2005) 1.57

Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med (2003) 1.56

Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm (2002) 1.55

Increased metabolic activity of indolent liver metastases after resection of a primary colorectal tumor. J Nucl Med (2008) 1.50

Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. Eur J Nucl Med Mol Imaging (2013) 1.49

68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging (2010) 1.48

A novel facile method of labeling octreotide with (18)F-fluorine. J Nucl Med (2010) 1.47

Scintigraphic imaging of infectious foci with an 111In-LTB4 antagonist is based on in vivo labeling of granulocytes. J Nucl Med (2005) 1.47

Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med (2010) 1.46

99mTc-HMPAO-labeled autologous versus heterologous leukocytes for imaging infection. J Nucl Med (2002) 1.41

The exceptional brain of Maurice Ravel. Med Sci Monit (2003) 1.41

Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum (2003) 1.39

Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer (2006) 1.38

Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. J Nucl Med (2006) 1.37

Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res (2013) 1.35

Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med (2006) 1.34

Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm (2003) 1.31

Image-quality assessment for several positron emitters using the NEMA NU 4-2008 standards in the Siemens Inveon small-animal PET scanner. J Nucl Med (2010) 1.30

Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res (2011) 1.29

Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice. Eur J Nucl Med Mol Imaging (2010) 1.26

Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. Circulation (2004) 1.26

Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res (2009) 1.24

Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes. Org Biomol Chem (2007) 1.24

Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging (2009) 1.23

PET and SPECT in osteomyelitis and prosthetic bone and joint infections: a systematic review. Semin Nucl Med (2010) 1.21

Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging. Proc Natl Acad Sci U S A (2011) 1.19

Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide. Nucl Med Biol (2007) 1.18

ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J Nucl Med (2010) 1.14

Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther (2010) 1.13

Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med Technol (2013) 1.12

Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother (2002) 1.12

Sequential 99mTc-hydrazinonicotinamide-annexin V imaging for predicting response to chemotherapy. J Nucl Med (2006) 1.12

Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med (2004) 1.11

PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors. J Nucl Med (2010) 1.11

A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents. Regul Pept (2006) 1.10

Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tomography. J Clin Oncol (2003) 1.07

Application of metal-free triazole formation in the synthesis of cyclic RGD-DTPA conjugates. Chembiochem (2008) 1.05

18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med (2010) 1.05

Reducing renal uptake of radiolabeled peptides using albumin fragments. J Nucl Med (2008) 1.05

Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol (2005) 1.05

The kinetic and biological activity of different loaded rhBMP-2 calcium phosphate cement implants in rats. J Biomed Mater Res A (2008) 1.04

Fluorinated amino acids for tumour imaging with positron emission tomography. Eur J Nucl Med Mol Imaging (2002) 1.03

Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging (2009) 1.03

Caffeine prevents protection in two human models of ischemic preconditioning. J Am Coll Cardiol (2006) 1.03

Comparative biodistribution of 12 ¹¹¹In-labelled gastrin/CCK2 receptor-targeting peptides. Eur J Nucl Med Mol Imaging (2011) 1.02

In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients. Cancer Res (2009) 1.02

Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging (2008) 1.02

Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody. J Nucl Med (2011) 1.00

PET imaging of αvβ₃ integrin expression in tumours with ⁶⁸Ga-labelled mono-, di- and tetrameric RGD peptides. Eur J Nucl Med Mol Imaging (2010) 1.00

Nuclear medicine imaging to predict response to radiotherapy: a review. Int J Radiat Oncol Biol Phys (2003) 1.00

Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study. Eur Neurol (2003) 1.00

Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. Radiother Oncol (2006) 0.99

Radionuclide imaging of tumor angiogenesis. Cancer Biother Radiopharm (2009) 0.99

Analysis of dendritic cell trafficking using EGFP-transgenic mice. Immunol Lett (2003) 0.98

Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin. Eur J Nucl Med Mol Imaging (2007) 0.98

Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response. Clin Cancer Res (2005) 0.97

SUV: from silly useless value to smart uptake value. J Nucl Med (2010) 0.97

Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer. J Nucl Med (2011) 0.96

Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides. Eur J Nucl Med Mol Imaging (2009) 0.96

Optimized labeling of NOTA-conjugated octreotide with F-18. Tumour Biol (2011) 0.95

Innovations in radiotherapy planning of head and neck cancers: role of PET. J Nucl Med (2009) 0.95

PET imaging of infection with a HYNIC-conjugated LTB4 antagonist labeled with F-18 via hydrazone formation. Nucl Med Biol (2007) 0.95

Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice. J Nucl Med (2010) 0.94

Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting. J Nucl Med (2005) 0.94

Immuno-PET of cancer: a revival of antibody imaging. J Nucl Med (2011) 0.94

Radiolabelled peptides for oncological diagnosis. Eur J Nucl Med Mol Imaging (2012) 0.93

Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. Clin Cancer Res (2003) 0.93

Combined delivery of BMP-2 and bFGF from nanostructured colloidal gelatin gels and its effect on bone regeneration in vivo. J Control Release (2012) 0.93

111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib. J Nucl Med (2010) 0.92

Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors. Bioconjug Chem (2004) 0.92

Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507. Clin Cancer Res (2011) 0.91

Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol (2012) 0.91

Incorporation of stromal cell-derived factor-1α in PCL/gelatin electrospun membranes for guided bone regeneration. Biomaterials (2012) 0.91

Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors. Amino Acids (2010) 0.90

Monoclonal antibody 14C5 targets integrin alphavbeta5. Mol Cancer Ther (2008) 0.90

Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: Lack of correlation with VEGF-A expression. Eur J Cancer (2008) 0.90

Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody. Int J Cancer (2008) 0.90

Molecular imaging of angiogenesis with SPECT. Eur J Nucl Med Mol Imaging (2010) 0.90

PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog. J Nucl Med (2012) 0.90

Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging. J Nucl Med (2011) 0.90

Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies. Int J Cancer (2013) 0.90

Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide. Int J Cancer (2007) 0.90

Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection. Arterioscler Thromb Vasc Biol (2009) 0.89